Management of inflammatory bowel disease

Postgraduate Medical Journal

Volumn 80, Issue 942, 2004, Pages 206-213

  Nayar, M ^a   Rhodes, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; CLARITHROMYCIN; COLESTYRAMINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; FOLIC ACID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; ORGANOARSENIC DERIVATIVE; PICOSULFATE SODIUM; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; SALAZOSULFAPYRIDINE; SUCRALFATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ACUTE DISEASE; BACTERIUM; BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOSCOPY; ENTERITIS; ENVIRONMENTAL FACTOR; FEVER; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; HEPATITIS; HEREDITY; HUMAN; ILEUM DISEASE; IMAGE ANALYSIS; IMMUNE RESPONSE; INTESTINE FLORA; LABORATORY TEST; LIFE EXPECTANCY; MORBIDITY; PANCREATITIS; PATHOGENESIS; PATIENT; PRACTICE GUIDELINE; PROCTITIS; REVIEW; SEPSIS; SMALL INTESTINE OBSTRUCTION; ULCERATIVE COLITIS;

CHRONIC DISEASE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; HUMANS;

EID: 2342445762     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2003.013722     Document Type: Review

References (58)

1. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. London: British Society of Gastroenterology, 1997.
2. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in celioc disease and inflammatory bowel disease. Gut 2000;46(suppl 1):i1-i8.
3. British Society of Gastroenterology. Inflammatory bowel disease. London: British Society of Gastroenterology, 1996.
4. Gore RM, Laufer I. Ulcerative and granulomatous colitis: idiopathic inflammatory bowel disease. In: Gore RM, Levine MS, Laufer I, eds. Textbook of gastrointestinal radiology. Philadelphia: WB Saunders, 1994:1098-141.
5. Scotiniotis I, Rubesin SE, Ginsberg GG. Imaging modalities in inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:391-421.
6. Balthazar EJ. CT of the gastrointestinal tract: principles and interpretation. Am J Roentgenol 1991;156:23-32.
7. Lee SD, Cohen RD. Endoscopy in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:119-32.
8. Parente F, Cucino C, Bollami S, et al. Focal gastric inflammatory infiltrates in inflammatory bowel disease: prevalence, immunohistochemical characteristics and diagnostic role. Am J Gastroenterol 2000;95:705-11.
9. Riddel RH. Pathology of inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory bowel disease. Philadelphia: WB Sounders, 2000:427.
10. Quinton JF, Sendid B, Reumaux D, et al. Anti Saccharomyces cerevesiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
11. Moore BA, Otterbein LE, Turler A, et al. Inhaled carbon monoxide suppresses the development of postoperative ileus in the murine small intestine. Gastroenterology 2003;124:377-91.
12. Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998;42:195-9.
13. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology 1998;115:525-32.
14. Marshall JK, Irvine EJ. Rectal corticosteraids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81.
15. Ryder SP, Walker RJ, Rhodes JM, et al. Rectal bismuth subsalicylate therapy for ulcerative colitis. Aliment Pharmacol Ther 1990;4:333-8.
16. Forbes A, Britton TC, Gazzard BG. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989;3:553-6.
17. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990;85:562-6.
18. Levine DS, Riff DS, Johnson LK, et al. Randomised double blind dose response comparison of balsalazide (6.75 g), balsalazide (2.25 g) and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:1398-407.
19. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-12.
20. Jewell DP, Caprilli R, Mortensen N, et al. Indication and timing for surgery for severe ulcerative colitis. Gastroenterol Int 1991;4:161-4.
21. Panas MZ, Wood MJ, Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 1993;34:1726-7.
22. Guslandi M. Nitric oxide in inflammatory bowel disease. Eur J Clin J Invest 1998;28:904-7.
23. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosparine for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997;92:1424-8.
24. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
25. Present DH, Chapman ML, Rubin PH, et al. Efficacy of 6-MP in refractory ulcerative colitis. Gastroenterology 1988;94:359A.
26. Colambel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
27. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
28. Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001;120:1093-9.
29. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetroting pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552-7.
30. Prantera C, Zannoni F, Scribono ML, et al. An antibiotic regime for the treatment of active Crohn's disease: a randomised controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
31. Moss AA, Carbone JV, Kressel HY. Radiologic and clinical assessment of brood-spectrum antibiotic therapy in Crohn's disease. Am J Roentgenol 1978;131:787-90.
32. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 2000;14:801-6.
33. Verma S, Brown S, Kirkwood B, et al. Polymeric versus elementol diet as primary treatment in active Crohn's disease: a randomised double blind trial. Am J Gastroenterol 2000;95:735-9.
34. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and o fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in poediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9.
35. Messori A, Brignola C, Trallor G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8.
36. Garcia JC, Persky SE, Bonis PA, et al. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol 2001;32:409-12.
37. Ursing B, Alm T, Barany F, et al. A comparative study of metronidozole and sulfosalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550-62.
38. Present DH, Rutgeerts P, Torgan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
39. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 ontisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6.
40. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
41. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group. Gastroenterology 2000;119:1461-72
42. Ghosh S, Goldin E, Gordon FH, et al. Natolizumab for active Crohn's disease: the notolizumab pan European study group. N Engl J Med 2003;348:24-32.
43. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
44. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 2000;6:16-20.
45. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-8.
46. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
47. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human gronulocyte-mocrophage colony-stimulating factor. Lancet 2002;360:1478-80.
48. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000;342:1633-7.
49. Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000299.
50. Burt RK, Traynor A, Oyama Y, et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 2003;101:2064-6.
51. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease: a population based cohort study. Am J Obstet Gynecol 1997;177:942-6.
52. Cuffari C, Bayless TM. Crohn's disease: influence of age at onset on clinical phenotype. Gastroenterol Int 1997;10:89-98.
53. Leiper K, London I, Rhodes JM. Adjuvant post operative therapy. Boilleres Clin Gastroenterol 1998;12:179-99.
54. Caprilli R, Cottone M, Tonelli F, et al. Two mesalamine regimens in the prevention of the post operative recurrence of Crohn's disease: a pragmatic double blind randomised control trial. Aliment Pharmacol Ther 2003;17:517-23.
55. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic calorectal cancer in patients with inflammatory bowel disease. Gut 2002;51(suppl V):v10-v12.
56. Rhodes JM. Surveillance for colitis-associated cancer: we cannot stop now. Dig Liver Dis 2002;34:319-21.
57. Karlen P, Kornfeld D, Brostrom O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case contral study. Gut 1998;42:711-14.
58. Travis SP. Review article: insurance risks for patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 1997;11:51-9.